Table 3 Overview of relevant literature in the treatment of Crowe III or IV dysplasia combined with subtrochanteric femoral shortening osteotomy
Study | Year | Hips (n) | DDH type | Femoral osteotomy | Mean age (Yrs) | Stem Type | Acetabular Type | Clinical results | Revision | Nonunion | Aseptic Loosening | Introp fracture | Heterotopic ossification | Nerve injury | Dislocation | Survival (end points) | FU (Yrs) | |||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Pre-operation | Post-operation | Act AL | Fem AL | Introp AF | Introp FF | |||||||||||||||
Ozan et al. | 2016 | 32 (25) | III&IV | Transverse | 51 (35–70) | Cementless | Cementless | HHS: 49 (25–72) | HHS: 87 (74–94) | 2 (6.2%) | 0 (0%) | 2 (6.2%) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | 3 (9.3%) | 93% (Loosening) | 5.1 |
Verettas et al. | 2015 | 66 (62) | III&IV | Transverse | 46 (24–74) | Cementless | Cementless | NA | NA | 4 (6%) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | 1 (1.5%) | 2 (3%) | 94% (Revision) | 9 |
Sofu et al. | 2015 | 73 (68) | III&IV | Transverse | 47 (31–69) | Cementless (Stryker) | Cementless (Stryker) | HHS: 38.6 ± 2.9 Pain: 16 ± 3.7 | HHS: 83.7 ± 6.8 Pain: 40 ± 4.6 | 6 (8.2%) | 4 (5.5%) | 0 (0%) | 4 (5.5%) | 0 (0%) | 0 (0%) | 2 (2.7%) | 0 (0%) | 1 (1.3%) | 87% (Femoral loosening; nonunion) | 5 |
Desteli et al. | 2015 | 60 (52) | III&IV | Transverse | 51 ± 13 | Cementless (HA) | Cementless (HA) | HHS: 39(25–60) Pain: 3 (1–5) Function: 3(1–5) Motion: 2 (1–4) | HHS:93(80–100) Pain: 5.4 (3–6) Function: 4(3–5) Motion: 5 (4–6) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | NA | 6.5 |
Ogawa et al. | 2011 | 6 (6) | III&IV | Transverse | 58 ± 7.2 | Cementless (S-ROM) | Cementless (Stryker; Depuy) | JOA: 35.5 ± 5.7 Pain: 7.0 ± 3.4 Function:9.3 ± 1.3 Motion:11.2 ± 1.3 | JOA: 72.3 ± 2.1 Pain: 35.8 ± 1.5 Function:14 ± 0.8 Motion: 16 ± 0.5 | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | 2 (33.3%) | 100% (Loosening) | 8.1 |
Akiyama et al. | 2011 | 15 (11) | III&IV | Transverse | 59 (42–77) | Cemented | Cemented | MAP: 8.1 ± 2.5 | MAP: 15.1 ± 1.3 | 3 (20%) | 3 (20%) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | 2 (13.3%) | 80% (Revision) | 3–10 |
Togrul et al. | 2010 | 21 (14) | III&IV | Transverse | 42 (33–52) | Cementless | Cementless | Pain: 2.9 (1–5) Motion: 4.4(3–5) Walking:3.7(2–5) | Pain: 5.2 (4–6) Motion:5.4(5–6) Walking:5.5(5–6) | 1 (4 .8%) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | 2 (9.5%) | 95% (Revision) | 3.4 |
Howie et al. | 2010 | 35 (28) | III&IV | Transverse | 47 (26–75) | Cemented | Cemented | OHS: 40.2 SF12: 79.6 | OHS: 26.7 SF12: 103.3 | 7 (20%) | 2 (3%) | 2 (3%) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | 2 (6%) | 3 (9%) | 80% (Revision) | 5.6 |
Biant et al. | 2009 | 28 (22) | III&IV | Transverse | 45 (23–74) | Cementless (S-ROM) | Cementless | HHS: 37 (19–69) SF12: NA WOMAC: 27 | HHS:83(44–100) SF12: 95.6 WOMAC: 23 | 4 (14%) | 0 (0%) | 2 (7.1%) | 0 (0%) | 0 (0%) | 2 (7.1%) | 0 (0%) | 1 (3.6%) | 0 (0%) | NA | 10 |
Park et al. | 2007 | 24 (23) | III&IV | Transverse | 49 (20–66) | Cementless | Cementless | HHS: 35.6 | HHS: 81.7 | 4 (17%) | 3 (12%) | 1 (4%) | 3 (13%) | 0 (0%) | 3 (13%) | 0 (0%) | 0 (0%) | 1 (4%) | 83% (Revision) | 4.7 |
Gotze et al | 2007 | 7 (7) | III&IV | Transverse | 42 (29–64) | Cementless | Cementless | HHS: 43 (29–61) | HHS: 77 (66–90) | 1 (14%) | 0 (0%) | 0 (0%) | 1 (14%) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | 86% (Revision) | 1.5 |
Onodera et al. | 2006 | 14 (13) | III&IV | Transverse | 55 (44–69) | Cementless | Cementless | HHS: 38 (15–55) | HHS: 82 (35–93) | 1 (7%) | 1 (7%) | 0 (0%) | 1 (7%) | 0 (0%) | 6 (43%) | 0 (0%) | NA | 1 (7%) | 93% (Revision) | 5 |
Erdemli et al. | 2005 | 25 (22) | III&IV | Transverse | 44 (28–61) | Cementless | Cementless | HHS: 37 Pain: 2.3 Function: 2.3 Motion: 2.3 | HHS: 95 Pain: 5.7 Function: 4.5 Motion: 4.4 | 4 (16%) | 1 (4%) | 0 (0%) | 2 (8%) | 1 (4%) | 2 (8%) | 1 (4%) | 1 (4%) | 1 (4%) | 84% (Revision) | 6 |
Masonis et al... | 2003 | 11 | III&IV | Transverse | 49 (21–70) | Cementless | Cementless | HHS: 33 (22–45) | HHS:74(42–100) | 5 (24%) | 1 (9%) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | 76% (Revision) | 5.8 |
|  | 10 | III&IV | Transverse | 49 (21–70) | Cemented | Cemented |  |  |  | 1 (10%) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | 3 (30%) |  | 5.8 | |
Bruce et al. | 2000 | 9 | III&IV | Transverse | 53 (26–77) | Cementless (S-ROM) | Cementless | HHS: 31 (20–25) | HHS: 81 (60–98) | 2 (22%) | 0 (0%) | 0 (0%) | 1 (11%) | 0 (0%) | 2 (22%) | 0 (0%) | 0 (0%) | 1 (11%) | 78% (Revision) | 4.7 |
Present study | 2016 | 56 (49) | III&IV | Transverse | 36 (19–45) | Cementless (S-ROM) | Cementless (S-ROM) | HHS: 40 (23–59) Pain: 2.2 (1–4) Function: 2 (1–3) Motion: 2.3(1–3) PCS: 11.6 (6–17) MCS: 14.4(9–20) | HHS: 87 (77–98) Pain: 5.5 (5–6) Function: 5 (4–6) Motion: 5.2(5–6) PCS: 22 (19–25) MCS: 25 (22–29) | 1 (1.8%) | 1 (1.8%) | 1 (1.8%) | 0 (0%) | 0 (0%) | 3 (5.4%) | 2 (3.6%) | 3 (5.4%) | 3 (5.4%) | 98% (Revision) | 10.1 |